نتایج جستجو برای: ctdna

تعداد نتایج: 831  

2017
Sandra Perdomo Patrice H. Avogbe Matthieu Foll Behnoush Abedi-Ardekani Violeta Lescher Facciolla Devasena Anantharaman Priscilia Chopard Florence Le Calvez-Kelm Marta Vilensky Jerry Polesel Ivana Holcatova Lorenzo Simonato Cristina Canova Pagona Lagiou James D. McKay Paul Brennan

The use of non-invasive biomarkers such as circulating tumor DNA (ctDNA) in head and neck tumors may be of relevance in early diagnosis and eventually improved outcome. We evaluated two different approaches from two case series in Europe and South America including (i) targeted screening of ctDNA mutations, and (ii) detection of TP53 mutations in plasma and oral rinses without previous knowledg...

2016
Evelyn Kidess-Sigal Haiyan E. Liu Melanie M. Triboulet James Che Vishnu C. Ramani Brendan C. Visser George A. Poultsides Teri A. Longacre Andre Marziali Valentina Vysotskaia Matthew Wiggin Kyra Heirich Violet Hanft Ulrich Keilholz Ingeborg Tinhofer Jeffrey A. Norton Mark Lee Elodie Sollier-Christen Stefanie S. Jeffrey

Treatment of advanced colorectal cancer (CRC) requires multimodal therapeutic approaches and need for monitoring tumor plasticity. Liquid biopsy biomarkers, including CTCs and ctDNA, hold promise for evaluating treatment response in real-time and guiding therapeutic modifications. From 15 patients with advanced CRC undergoing liver metastasectomy with curative intent, we collected 41 blood samp...

2017
Jin Wang Hua Bai Chaoyu Hong Jie Wang Tong‐hua Mei

BACKGROUND We investigated whether different sampling time-points within one day would influence epidermal growth factor receptor mutation (EGFRm) status in plasma and evaluated the clinical outcomes according to the quantity analysis of EGFRm in circulating tumor DNA (ctDNA) in non-small-cell lung cancer (NSCLC). METHODS EGFR-tyrosine kinase inhibitor naïve advanced NSCLC patients who carrie...

2016
Kei A. Sato Tsuyoshi Hachiya Takeshi Iwaya Kohei Kume Teppei Matsuo Keisuke Kawasaki Yukito Abiko Risaburo Akasaka Takayuki Matsumoto Koki Otsuka Satoshi S. Nishizuka Alvaro Galli

BACKGROUND Circulating tumor DNA (ctDNA) carries information on tumor burden. However, the mutation spectrum is different among tumors. This study was designed to examine the utility of ctDNA for monitoring tumor burden based on an individual mutation profile. METHODOLOGY DNA was extracted from a total of 176 samples, including pre- and post-operational plasma, primary tumors, and peripheral ...

2017
Giulia Siravegna Elena Geuna Benedetta Mussolin Giovanni Crisafulli Alice Bartolini Danilo Galizia Laura Casorzo Ivana Sarotto Maurizio Scaltriti Anna Sapino Alberto Bardelli Filippo Montemurro

BACKGROUND Central nervous system (CNS) involvement contributes to significant morbidity and mortality in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) and represents a major challenge for clinicians. Liquid biopsy of cerebrospinal fluid (CSF)-derived circulating tumour DNA (ctDNA) harbours clinically relevant genomic alterations in patien...

2016
Ao Huang Xin Zhang Shao-Lai Zhou Ya Cao Xiao-Wu Huang Jia Fan Xin-Rong Yang Jian Zhou

PURPOSE Circulating tumor DNA (ctDNA) is increasingly recognized as liquid biopsy to profile tumor genome. Droplet digital PCR (ddPCR) is a highly sensitive and easily operable platform for mutant detection. Here, we tried to detect ctDNA in hepatocellular carcinoma (HCC) patients using ddPCR. METHODS Studies sequencing the genome of HCCs and COSMIC (Catalogue of Somatic Mutations in Cancer) ...

2017
Sarah B. Ng Clarinda Chua Matthew Ng Anna Gan Polly SY Poon Melissa Teo Cherylin Fu Wei Qiang Leow Kiat Hon Lim Alexander Chung Si-Lin Koo Su Pin Choo Danliang Ho Steve Rozen Patrick Tan Mark Wong William F. Burkholder Iain Beehuat Tan

Circulating tumour DNA (ctDNA) has the potential to be a specific biomarker for the monitoring of tumours in patients with colorectal cancer (CRC). Here, our aim was to develop a personalised surveillance strategy to monitor the clinical course of CRC after surgery. We developed patient-specific ctDNA assays based on multiplexed detection of somatic mutations identified from patient primary tum...

Journal: :Plant physiology 1981
J Aldrich R A Cattolico

Chloroplast DNA (ctDNA) from the marine chromophytic alga, Olisthodiscus luteus, has been isolated using a whole cell lysis method followed by CsCl-Hoechst 33258 dye gradient centrifugation. This DNA, which has a buoyant density of 1.691 grams per cubic centimeter was identified as plastidic in origin by enrichment experiments. Inclusion of the nuclease inhibitor aurintricarboxylic acid in all ...

Journal: :Current opinion in oncology 2015
Isabelle Gingras Roberto Salgado Michail Ignatiadis

PURPOSE OF REVIEW The aim of this review is to highlight the recent advances (in the past 12 months) concerning circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in oncology. RECENT FINDINGS The value of CTCs as a prognostic biomarker is now well validated in breast, colon, and prostate cancer, but no trial has yet demonstrated that modifying treatment according to CTCs is supe...

2017
Gaowei Fan Kuo Zhang Jiansheng Ding Jinming Li

EGFR (exon 19 and exon 21) mutations in patients with advanced non-small cell lung cancer (NSCLC) treated by EGFR-TKIs are associated with a better survival; while KRAS mutations predict a worse prognosis. However, there are divergent findings regarding the prognostic value of EGFR and KRAS mutations in circulating tumor DNA (ctDNA). We aimed to summarize the evidence for the use of circulating...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید